ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
67 announcements
Promoter Sachin D. Patel proposes to acquire up to 0.50% stake in Gujarat Themis Biosyn. The Rs.20 Crore inter-se transfer increases his holding to 2.77%.
Gujarat Themis Biosyn initiated arbitration against Optimus Drugs claiming Rs. 90.24 Crore. The dispute involves breached 'Take-or-Pay' obligations and terminated supply agreements.
Gujarat Themis Biosyn amicably settled its commercial dispute with Optimus Drugs Private Limited. The arbitration disposal results in no material financial impact or penalties.
Shareholders approved a special resolution to raise funds via a Qualified Institutions Placement. The approval enables the company to issue new equity shares.
Gujarat Themis Biosyn announced shareholders approved fund raising via Qualified Institutions Placement. The special resolution passed with 99.97% majority through a postal ballot process.
Promoter Sachin D. Patel will acquire up to 5.25 lakh shares worth Rs.20 Cr from Pharmaceutical Business Group (India) Ltd. His stake rises from 2.29% to 2.77%.
CTL Trusteeship Ltd filed a SAST Reg 29(1) disclosure on encumbrances over PBGIL shares. This creates an indirect encumbrance over Gujarat Themis Biosyn Ltd shares.
Gujarat Themis Biosyn Ltd reported a transfer of 24.97 lac shares to promoter Sachin D. Patel, raising his stake to 2.29%. The deal is an off‑market promoter acquisition.
GTBL is transforming into a global CDMO platform via acquisitions of MicroBiopharm Japan and Sanofi's anti-TB portfolio. FY26 revenue stood at INR 16,582 Lakhs with a 45.55% EBITDA margin.
Gujarat Themis Biosyn initiated arbitration against Optimus Drugs claiming ₹90.24 Crore. The dispute follows a supply agreement termination and breach of take-or-pay obligations.
Gujarat Themis Biosyn faces an arbitration claim of ₹113.80 Crore from Optimus Drugs. The company expects no financial implication from this litigation.
Gujarat Themis Biosyn Limited submitted a corrected XBRL filing. This corrects the omission of Earnings Per Share from previous results.
Gujarat Themis Biosyn Ltd promoter Sachin Patel proposes to acquire up to 2.6 million shares worth ₹100 Crore. The stake will rise to about 2.38% post‑transfer.
Gujarat Themis Biosyn Limited has issued a postal ballot notice to seek shareholder approval for a Rs. 1,000 Crore QIP. The move aims to fund growth and strategic projects.
Gujarat Themis Biosyn's board approved raising ₹1,000 Crore through a Qualified Institutions Placement. The company also plans a preferential issue of equity shares to non-promoters.
Gujarat Themis Biosyn announced the approval of special resolutions via postal ballot. Shareholders passed resolutions to increase borrowing limits and loan/investment capacities with requisite majorities.
Gujarat Themis Biosyn scheduled a board meeting for June 6, 2026. Directors will evaluate fund-raising options including QIP or preferential allotment to strengthen the capital base.
Gujarat Themis Biosyn incorporated a wholly owned pharmaceutical subsidiary in Ireland with €1,00,000 capital. The move marks an international expansion into European markets.
Gujarat Themis Biosyn Ltd submitted its Annual Secretarial Compliance Report for FY2024-25. The report confirms overall regulatory adherence with minor historical compliance observations noted.
Gujarat Themis Biosyn Limited reports Q4 FY26 revenue of ₹44.23 cr (+17.2% YoY) and PAT of ₹10.89 cr. Management announced two major inorganic acquisitions to pivot towards a CDMO model.
Gujarat Themis Biosyn Ltd reported revenue from operations of ₹44.2 Cr (+17.2% YoY) and net profit of ₹10.9 Cr (-9.2% YoY) for Q4 FY26.
Gujarat Themis Biosyn approved FY26 financial results and recommended a ₹7.30 Crore final dividend. The Board also proposed a preferential equity issue to non-promoters.
Gujarat Themis Biosyn is acquiring MicroBiopharm Japan for ₹1,300 Crore to expand its CDMO capabilities. This strategic move strengthens its position in precision fermentation and biotechnology.
Gujarat Themis Biosyn (GTBL) announced the acquisition of 100% of MicroBiopharm Japan (MBJ) for JPY 21.5 Bn (~INR 1,300 Cr), transitioning GTBL into a globally integrated fermentation-based CDMO.
Gujarat Themis Biosyn Limited will acquire 100% of Japan-based MicroBiopharm Japan for ₹1,290 Crore. This strategic acquisition expands GTBL's CDMO capabilities into advanced precision fermentation.
Gujarat Themis Biosyn Limited incorporated a wholly owned subsidiary, Themis Biosyn Japan Limited, in Japan. This strategic expansion marks the company's direct entry into the Japanese market.
Gujarat Themis Biosyn incorporated a wholly owned subsidiary in Japan named Themis Biosyn Japan Limited. This expansion strengthens the company's international pharmaceutical business footprint.
Gujarat Themis Biosyn scheduled a May 25, 2026 board meeting. Directors will consider FY26 audited financial results and recommend a potential equity dividend.
Gujarat Themis Biosyn Limited has issued a Postal Ballot notice to seek shareholder approval via special resolutions. The resolutions include increasing the company's borrowing limits, creating charges on assets, and enhancing limits for loans, guarantees, and investments. Voting concludes on June 4, 2026.
Gujarat Themis Biosyn Limited has issued a Postal Ballot notice to seek shareholder approval via special resolutions. The resolutions propose increasing the company's borrowing limits and limits for loans, guarantees, and investments under Sections 180 and 186 of the Companies Act, 2013. The voting period ends on June 4, 2026.